Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

UnitedHealth Group

The market rally is unjustified by deteriorating economic fundamentals and $300 billion per month in reverse money printing. A recession is still likely, and current earnings expectations are wildly optimistic. A 20% to 35% market correction within 9 months is likely. Smart investors know that hiding under the bed isn't the answer. Now is the time for safety and quality first, and prudent valuation and sound risk management.

2 Buffett-Style Blue-Chip Buys For What's Coming Next

Home Depot

Infosys

Occidental Petroleum

Pfizer

PayPal

Thermo Fisher Scientific

While the smaller-capitalization trades tend to attract the most speculative attention, for reliable upside prospects, investors may want to consider blue-chip stocks to buy. To better understand the motivation behind targeting these stalwarts, a baseball analogy may be helpful.

Ready for a Rebound: 7 Blue-Chips Set to Regain Their Market Mojo

Apple

Abbott Labs

Air Products and Chemicals

Caterpillar

Colgate-Palmolive

Clorox

General Dynamics

General Mills

Hormel Foods

Procter & Gamble

Starbucks

AT&T

Verizon

Without rehashing the wild ride we experienced in the market so far in 2023, I could find comfort in one thing, my dividends. Hitting the elusive four-digit mark in May has been a welcome sign for me on my dividend growth journey. In May 2022 I brought in $862.43 and this May I have seen a year over year increase of 23.8%.

Dividend Income Update May 2023

Broadcom

Chevron

Coca-Cola

There are several reasons to seek out high-cash-flow stocks. In the simplest terms, companies that generate strong cash flow can pay – and increase – dividends, develop new products and buy back shares among other things.

Unlock the Potential of These 7 Cash-Flow Machines

AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.

AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals

Coherus Biosciences will soon likely commercialize a generic copy of Humira. Humira is AbbVie's largest-grossing drug, and one of the most lucrative of all time.

This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?

AbbVie's growth prospects remain strong despite the impending decline in revenue from Humira, thanks to promising alternatives Skyrizi, Rinvoq, and the recently FDA-approved Linzess. The company's robust R&D investments, diverse product lineup, and consistent presence in a burgeoning pharmaceutical manufacturing industry position it well for long-term growth. Despite regulatory risks, AbbVie's impressive ROIC over the past decade and exceptional dividend yield reflect its financial strength.

AbbVie: A Pharmaceutical Powerhouse Despite Humira Challenges

Roche Holding AG

The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG's experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from AbbVie Inc.

Roche's cancer therapy gets US FDA nod, heating up competition with AbbVie

In ulcerative colitis patients with a clinical response to risankizumab induction treatment, a significantly higher proportion of patients treated with risankizumab (180 mg or 360 mg) achieved the primary endpoint of clinical remissiona (per Adapted Mayo Score) at week 52 compared to withdrawal from risankizumab treatment 1 Key secondary endpoints were met, including endoscopic improvementb, histologic endoscopic mucosal improvement c and steroid-free remission d at one year Safety results in this study were consistent with the known safety profile of risankizumab, with no new safety risks observed1 Building on AbbVie's growing gastroenterology portfolio, risankizumab is an IL-23 inhibitor being evaluated as a treatment for adults with moderate to severe ulcerative colitis and approved for Crohn's disease, psoriatic arthritis and psoriasis1 NORTH CHICAGO, Ill. , June 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI®, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint of clinical remission (per Adapted Mayo Score) at week 52, as well as key secondary endpoints in adult patients with moderately to severely active ulcerative colitis.1 In the COMMAND maintenance study, patients from the Phase 2b/3 INSPIRE study who responded to induction treatment were re-randomized to receive risankizumab 180 mg SC, 360 mg SC or withdrawal from risankizumab treatment (risankizumab intravenous [IV] induction-only control group).1 Approximately 75% of patients previously failed at least one advanced therapy (biologics, JAK inhibitors and/or S1P receptor modulators) for ulcerative colitis.1 A significantly higher proportion of patients who received risankizumab 180 mg or 360 mg achieved clinical remission at week 52: 40% and 38%, respectively, compared to 25% in the induction-only control group (p

Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients

BeiGene

BeiGene Ltd.'s ADR BGNE was down more than 7% premarket on Thursday after AbbVie's ABBV Pharmacyclics unit filed a patent-infringement lawsuit against the biotech company.

BeiGene shares drop after AbbVie unit files patent-infringement lawsuit over cancer drug

Coherus BioSciences

Coherus BioSciences Inc said on Thursday it had agreed to resolve a dispute over its plans to launch a lower-priced version of AbbVie Inc's Humira, its blockbuster rheumatoid arthritis drug.

Abbvie, Coherus agree to resolve dispute over Humira biosimilar

AbbVie Inc. (NYSE:ABBV ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 14, 2023 11:00 AM ET Company Participants Rob Michael - President and Vice Chair Jeff Stewart - Chief Commercial Officer Roopal Thakkar - Chief Medical Officer Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Here we go.

AbbVie Inc. (ABBV) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

20 GRANT RECIPIENTS ARE SELECTED FROM MORE THAN 6,500 APPLICATIONS TO RECEIVE FUNDING, YEAR-LONG MENTORSHIP, AND COACHING IRVINE, Calif. , June 13, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the 20 incredible women entrepreneurs who will receive funding and mentorship through the BOTOX® Cosmetic and IFundWomen grant program.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at Maxim Group's Virtual Healthcare Conference.

Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group's Virtual Healthcare Conference

Accenture Plc

Adobe

Agree Realty

Automatic Data Processing

AGCO

Amgen

Amazon

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Booz Allen Hamilton Hld

Brookfield Asset Management

Brookfield Renewable Partners

SPDR Bloomberg 1-3 Month T-Bill ETF

Blackrock Inc

Bristol-Myers

Brookfield Corp

Broadridge Financial

British American Tobacco

Blackstone Group

My passive income stream increased by 25.59% YoY in April 2023 and 40.02% YoY in May 2023, with a year-to-date growth of 29.99%. I have been taking advantage of high yields on money market funds and short-term treasury ETFs, transitioning about 6.5% of my total portfolio value from a 0% yield into a high-yielding position. I have been making selective reinvestments and trades to increase my passive income stream and accelerate my journey towards financial freedom.

Nicholas Ward's Dividend Growth Portfolio: April And May Review

Bank of America

Deere & Company

Johnson & Johnson

Kinder Morgan

The market probably feels like the movie Groundhog's Day for many investors. The major indexes continue to trade within a range, which is frustrating both bulls and bears.

7 Top Blue-Chip Stocks to Buy in June 2023

Novo Nordisk

Novo Nordisk is forecasting revenue and operating profit growth this year. AbbVie said it expects to return to revenue growth in 2025.

Better Long-Term Buy: AbbVie or Novo Nordisk?

Applied Materials

Best Buy

Cisco Systems

Expeditors International of Washington

Fastenal

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 1.84% in May, outperforming the S&P 500 by 1.40%. Year-to-date the portfolio is up 6.66% and trailing the S&P 500 by 2.99%. Since inception, the portfolio is generating alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Passively Outpacing The Market

News for AbbVie Stock (ABBV)